title: Discovery and characterization of novel small molecule inhibitors of human Cdc25B dual specificity phosphatase.
abstract: Cdc25A and Cdc25B dual-specificity phosphatases are key regulators of cell cycle transition and proliferation. They have oncogenic properties and are overexpressed in many human tumors. Because selective Cdc25 phosphatase inhibitors would be valuable biological tools and possible therapeutic agents, we have assayed a small molecule library for in vitro inhibition of Cdc25. We now report the identification of two new structurally distinct classes of Cdc25 inhibitors with cellular activity. The cyclopentaquinoline 3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-4,8-dicarboxylic acid (5661118) and the naphthofurandione 3-benzoyl-naphtho[1,2-b]furan-4,5-dione (5169131) had in vitro IC50 values of 2.5 to 11 microM against recombinant Cdc25 and were less potent inhibitors of other phosphatases. Unlike 5661118, 5169131 caused reversible inhibition of Cdc25B and displayed competitive inhibitor kinetics. No growth inhibitory activity was seen with 5661118, whereas 10 to 30 microM 5169131 caused G1/S and G2/M arrest. We also found that 5169131 inhibited human PC-3 prostate and MDA-MB-435 breast cancer cell proliferation. Concentration-dependent Tyr15 hyperphosphorylation was seen on cyclin-dependent kinase with a 1-h 5169131 treatment, consistent with Cdc25 inhibition. Cells resistant to DNA toposiomerase II inhibitors were as sensitive to 5169131 as parental cells, indicating that this quinone compound does not inhibit topoisomerase II in vivo. Molecular modeling was used to predict a potential interaction site between the inhibitor and Cdc25B and to provide insights as to the molecular origins of the experimental observations. Based on its kinetic profile and cellular activity, we suggest that 5169131 could be an excellent tool for further studies on the cellular roles of Cdc25.
authors.affiliation: Department of Pharmacology, University of Pittsburgh, PA 15261-0001, USA.
authors.forename: Marni
authors.initials: M
authors.lastname: Brisson
authors.forename: Theresa
authors.initials: T
authors.lastname: Nguyen
authors.forename: Andreas
authors.initials: A
authors.lastname: Vogt
authors.forename: Jack
authors.initials: J
authors.lastname: Yalowich
authors.forename: Angela
authors.initials: A
authors.lastname: Giorgianni
authors.forename: Dror
authors.initials: D
authors.lastname: Tobi
authors.forename: Ivet
authors.initials: I
authors.lastname: Bahar
authors.forename: Corey R J
authors.initials: CR
authors.lastname: Stephenson
authors.forename: Peter
authors.initials: P
authors.lastname: Wipf
authors.forename: John S
authors.initials: JS
authors.lastname: Lazo
mesh_terms: D002453:Cell Cycle / Q000187:drug effects; D018797:Cell Cycle Proteins / Q000037:antagonists & inhibitors*; D002455:Cell Division / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000138:chemical synthesis / Q000302:isolation & purification*; D005663:Furans / Q000138:chemical synthesis / Q000302:isolation & purification*; D006801:Humans; D009285:Naphthoquinones / Q000138:chemical synthesis / Q000302:isolation & purification*; D013379:Substrate Specificity; D014407:Tumor Cells, Cultured; D020687:cdc25 Phosphatases / Q000037:antagonists & inhibitors*
chemical_list: D018797:Cell Cycle Proteins; D004791:Enzyme Inhibitors; D005663:Furans; D009285:Naphthoquinones; C517008:CDC25B protein, human; D020687:cdc25 Phosphatases